The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study

期刊论文
发表日期：

2024年4月28日

查看全文

Sho Sato,
Takashi Ssuzuki,
Takashi Chinen,
Hironori Yamaguchi,
Yusuke Suzuki,
Nobukazu Hokamura,
Zenichiro Saze,
Koji Kono,
Keita Takahashi,
Fumiaki Yano,
Chikara Kunisaki,
Takashi Kosaka,
Itaru Endo,
Yasushi Ichikawa,
Yutaka Miyawaki,
Hiroshi Sato,
Hideaki Shimada

摘要

Background

The real-world efficacy, feasibility, and prognostic factors of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer are not fully established.

Methods

This multi-institutional retrospective cohort study evaluated 71 consecutive patients treated with immune-checkpoint inhibitor combination therapy for esophageal cancer between March 2021 and December 2022. We assessed tumor response, safety, and long-term survival.

Results

In patients with measurable lesions, the response rate was 58%, and the disease control rate for all enrolled patients was 80%. Five patients (7.0%) underwent successful conversion surgery. Grade 3 or higher immune-related adverse events occurred in 13% of patients, and one patient (1.4%) died due to cholangitis. Median progression-free survival was 9.7 (95% confidence interval: 6.5–not reached). C-reactive protein levels and performance status were identified as significant predictors of progression-free survival through Cox proportional hazards analysis.

Conclusions

Immune-checkpoint inhibitor combination therapy for esophageal cancer demonstrated comparable tumor response, safety, and long-term survival to previous randomized clinical trials. Patients with good performance status and low C-reactive protein levels may be suitable candidates for this treatment.